布美卡因 | 30103-44-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 布美卡因
• 英文名称: Marcain
• 英文别名: pyromecaine；Bumecainum；Bumecaine；1-butyl-N-(2,4,6-trimethylphenyl)pyrrolidine-2-carboxamide
• CAS: 30103-44-7
• 化学式: C₁₈H₂₈N₂O
• 分子量: 288.433
• InChiKey: VEPZOLKTNZOTTQ-UHFFFAOYSA-N

物化性质

• 沸点：
  416.6±45.0 °C(Predicted)
• 密度：
  1.038±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3,3'-[(1,2-dioxoethane-1,2-diyl)diimino]dipropanoic acid 、 布美卡因 生成 1-butyl-N-(2,4,6-trimethylphenyl)pyrrolidine-2-carboxamide;3-[[2-(2-carboxyethylamino)-2-oxoacetyl]amino]propanoic acid
  参考文献：
  名称：

  PETYUNIN, G. P.;ABDULLAEVA, B. M.;CHUBENKO, A. V., 1991) 15 S., FNIITEHXIM G. CHERKASSY, 7-XP91

  摘要：

  DOI：

文献信息

• Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans
  申请人：Regen BioPharma, Inc.

  公开号：US20180214413A1

  公开（公告）日：2018-08-02

  The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans.

  目前的技术是针对核受体活性调节剂，具体是针对NR2F6活性的调节和利用NR2F6化合物的调节，以及通过将本文描述的化合物用于人体来进行免疫调节和调节癌症干细胞活性。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• HAEMOSTATIC AND WOUND HEALING MEDICINE
  申请人：Limited Liability Company "Tectum"

  公开号：EP3278815A1

  公开（公告）日：2018-02-07

  The present invention refers to medicine, namely hemostatic and wound healing agents, and can be used to stop bleeding of various severity, including venous, as well as to heal wounds and cuts obtained as a result of mechanical action on the epidermal and muscular layers of tissues. For this, a hemostatic agent containing an active gelling agent based on chitosan and / or its derivatives is used, characterized in that it contains chitosan, its salts and / or its derivatives in the form of a gel having a three-dimensional crosslinked structure as a polymer matrix and components of natural thrombus formation in the form of organic calcium compounds, organic acid and water coordinated on this matrix at a certain ratio of components. The technical result of the invention consists in accelerating the arrest of bleeding of various severity and creating an antibacterial effect.

  本发明指的是药物，即止血剂和伤口愈合剂，可用于止住各种严重程度的出血，包括静脉出血，以及愈合由于对组织表皮层和肌肉层的机械作用而造成的伤口和割伤。为此，使用了一种含有以壳聚糖和/或其衍生物为基础的活性胶凝剂的止血剂，其特征在于它含有壳聚糖、其盐和/或其衍生物，以具有三维交联结构的凝胶形式作为聚合物基质，以及以有机钙化合物、有机酸和水的形式按一定比例配位在该基质上的天然血栓形成成分。 本发明的技术成果包括加速止住各种严重程度的出血，并产生抗菌效果。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。